Stock Insider Trading (from SEC Form 4)

CTSO / Cytosorbents Corp insiders include Chan Phillip P. (President and CEO), Gunton James T. (), BATOR MICHAEL G. (), Sobel Alan D. (), NJTC INVESTMENT FUND, LP (), Capponi Vincent (Chief Operating Officer), Kraus Al (), Mortensen Eric R. (Chief Medical Officer), Jones Edward Raymond () BLOCH KATHLEEN P. (Chief Financial Officer), and BARTLETT ROBERT HAWES (Chief Medical Officer), .

Cytosorbents Corp insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.
File Date
Tran Date
Insider Code Shares Post Shares Percent
Tran Value Post Value Percent
2018-01-18 2018-01-12 BLOCH KATHLEEN P. Chief Financial Officer
S -12,400 237,638 -4.96 7.75 -96,100 1,841,694 -5.22
2018-01-18 2018-01-16 Capponi Vincent Chief Operating Officer
F -35,257 283,805 -11.05 7.80 -275,005
2017-06-13 2017-06-09 Mortensen Eric R. Chief Medical Officer
P 2,500 2,500 4.0398 10,100 10,100 100.00
2017-06-12 2017-06-09 BATOR MICHAEL G. Director
P 1,500 70,500 2.17 4.12 6,180 290,460 2.13
2017-06-08 2017-06-08 Chan Phillip P. President and CEO, Director
P 3,700 399,907 0.93 4.00 14,800 1,599,628 0.93
2017-06-08 2017-06-08 Jones Edward Raymond Director
P 2,000 68,500 3.01 3.9995 7,999 273,966 2.92
2017-02-28 2017-02-24 Sobel Alan D. Director
A 6,000 66,000 10.00
2017-02-28 2017-02-24 Kraus Al Director
A 6,000 121,746 5.18
2016-01-13 2015-12-30 NJTC INVESTMENT FUND, LP 10% Owner
J -1,120,219 2,554,999 -30.48
2015-04-10 2015-04-08 BARTLETT ROBERT HAWES Chief Medical Officer
A 30,000 30,000
2015-04-10 2015-04-08 Gunton James T. Director, 10% Owner
A 55,000 55,000
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related News Stories

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

2018-02-15 reuters

Biotech Forum Daily Digest: Synergy's CEO Leaves, Shareholders Cheer!

2017-12-22 seekingalpha
The biotech sector has a decent sized acquisition as 2017 comes to a close.  Roche is buying oncology concern Ignyta for a 75% premium.  M&A should see uptick in 2018. (408-1)

Biotech Forum Daily Digest: What Now For Sarepta?

2017-11-21 seekingalpha
Biotech fell to begin the holiday shortened trading week, continuing a bout of poor performance in the fourth quarter of this year. (143-1)

Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day everyone and welcome to the CytoSorbents Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will being the call – we will open the call for your questions. Please be advised that the call will be recorded as the Company's request. (13-1)

CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress

2017-09-26 prnewswire
MONMOUTH JUNCTION, N.J., Sept. 26, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announced the launch and immediate availability of its CytoSorb Therapeutic ECMO™ Kit, at the 30th Annual European Society of Intensive Care Medicine (ESICM) Congress in Vienna, Austria (September 23-27, 2017). (15-0)

Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®

2017-09-25 prnewswire
MONMOUTH JUNCTION, N.J., Sept. 25, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ill and cardiac surgery patients around the world, highlighted the recent publication of a study entitled "Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study" in the Journal of Artificial Organs. (15-0)